Isis chronicles

Isis chroniclesIsis shares hit bottom in March 2003 with a major trial failure in cancer (see G below) at the same time the biotech sector was hitting its post-genomics nadir. But while the rest of the group recovered, ISIS shares went sideways, accompanied by a couple of restructuring announcements. Now, with two new next-generation antisense compounds in Phase II (ISIS 301012 and ISIS 113715), investors may be reappearing. ISIS’s weekly stock moves are tracked against selected events since the start of 2002.

A.1/7/02 - Eyetech, now part of OSI (OSIP), non-exclusively licenses certain IP from ISIS relating to Macugen, an aptamer that inhibits VEGF to treat ophthalmic diseases...